Community-acquired pneumonia in the immunocompromised patients: an observational study from a single center, Turkey

Basit Öğe Kaydı
dc.contributor.authorYılmaz, Ezgi
dc.contributor.authorBenli, Aysun
dc.contributor.authorBaşaran, Seniha
dc.contributor.authorŞimşek Yavuz, Serap
dc.contributor.authorÇağatay, Atahan
dc.contributor.authorÖncül, Mustafa Oral
dc.contributor.authorEraksoy, Haluk
dc.date.accessioned2025-11-07T07:24:35Z
dc.date.available2025-11-07T07:24:35Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı
dc.description.abstractPurpose: Immunocompromised hosts are underrepresented in clinical trials. The goal of the study to search for the unmet needs in the management of CAP in immunocompromised hosts. Patients and Methods: An observational study was conducted with CAP patients documented immunocompromise or those aged over 65 who have at least one chronic visceral disease. We clinically assessed the eligible patients at the time of the presentation with a follow-up assessment on day three of admission. The data were statistically analyzed to assess the impact of variables on mortality. Results: During a 15-month study period, 140 CAP patients were observed. The overall 30-day mortality rate was 17.8%. The mortality rate was significantly higher in patients with sputum cultures positive for Pseudomonas aeruginosa, or two bacteria (p=0.049). Tachypnea was a stronger predictor of mortality. Failure to achieve a treatment response within three days of treatment identified the population with the worst outcomes. Less than half of such patients survived past one month. Conclusion: Dynamic response assessment emerged as potentially the strongest predictor of outcomes in CAP of susceptible hosts. We propose that immunocompromised CAP patients who fail to respond early to treatment face extremely high rates of mortality, identifying an unmet need.
dc.identifier.citationYılmaz, E., Benli, A., Başaran, S., Şimşek Yavuz, S., Çağatay, A., Öncül, M. O. ... Eraksoy, H. (2024). Community-acquired pneumonia in the immunocompromised patients: an observational study from a single center, Turkey. Infection and Drug Resistance, 17, 4875-4885. http://dx.doi.org/10.2147/IDR.S480520
dc.identifier.doi10.2147/IDR.S480520
dc.identifier.endpage4885
dc.identifier.issn1178-6973
dc.identifier.pmid39524981
dc.identifier.scopus2-s2.0-85209230229
dc.identifier.scopusqualityQ2
dc.identifier.startpage4875
dc.identifier.urihttp://dx.doi.org/10.2147/IDR.S480520
dc.identifier.urihttps://hdl.handle.net/20.500.12511/13174
dc.identifier.volume17
dc.identifier.wosWOS:001349741800001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorYılmaz, Ezgi
dc.institutionauthorid0000-0002-4181-5674
dc.language.isoen
dc.relation.ispartofInfection and Drug Resistance
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectCAP
dc.subjectCommunity Acquired Pneumonia
dc.subjectImmunocompromised Patient
dc.subjectImpaired Immunity
dc.subjectInitial Response to Treatment
dc.titleCommunity-acquired pneumonia in the immunocompromised patients: an observational study from a single center, Turkey
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Yılmaz-Ezgi-2024.pdf
Boyut:
1.66 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu